Theralase Technologies Q1 2023 Earnings Report

Theralase Technologies EPS Results

• Actual EPS: -C$0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Theralase Technologies Revenue Results

• Actual Revenue: $0.21 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Theralase Technologies Announcement Details

• Quarter: Q1 2023
• Date: 5/30/2023
• Time: N/A

Theralase Technologies (CVE:TLT), a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.